Clinical trials in Freiburg Im Breisgau – page 14

529 clinical trials in Freiburg Im Breisgau, Germany across 1 research site. Every trial is listed in the EU Clinical Trials Register and updated daily.

Our site in GermanyKlinischeStudien.de

Freiburg Im Breisgau at a glance

529

clinical trials

Research sites1

Quick filters

529 trials in Freiburg Im Breisgau

Open in trial search

B-cell lymphoma+2

Recruiting

Long-Term Follow-Up Study for Patients Treated with CAR T-Cell Therapy Using PHE885, YTB323, and Tisagenlecleucel

Registered drugNo placebo

Long-Term Follow-Up Study for Patients Treated with CAR T-Cell Therapy Using PHE885, YTB323, and Tisagenlecleucel

Registered drugNo placebo

Germany

Participants:0–17 years · 18–64 years · 65+ years
Substances:Tisagenlecleucel
Sponsor:Novartis Pharma Services AG

Contact Research Centre

Plasma cell myeloma

Recruiting

Study of Iberdomide and Isatuximab for Maintenance Therapy in Patients with Newly Diagnosed Multiple Myeloma After Stem-Cell Transplantation

Registered drugNo placebo

Study of Iberdomide and Isatuximab for Maintenance Therapy in Patients with Newly Diagnosed Multiple Myeloma After Stem-Cell Transplantation

Registered drugNo placebo

Germany

Participants:18–64 years · 65+ years
Substances:Dexamethasone
Sponsor:Universitaetsklinikum Heidelberg AöR

Contact Research Centre

Fallopian tube cancer+5

Recruiting

Study on Niraparib, Carboplatin, and Paclitaxel for Advanced Ovarian Cancer Patients After Tumor Removal

Registered drugNo placebo

Study on Niraparib, Carboplatin, and Paclitaxel for Advanced Ovarian Cancer Patients After Tumor Removal

Registered drugNo placebo

Germany

Participants:18–64 years · 65+ years
Substances:Carboplatin
Sponsor:Nord Ostdeutsche Gesellschaft Fuer Gynaekologische Onkologie e.V.

Contact Research Centre

Prostate cancer metastatic

Recruiting

Study of AZD5305 with Abiraterone Acetate and Darolutamide in Men with Metastatic Castration-Sensitive Prostate Cancer

Registered drug

Study of AZD5305 with Abiraterone Acetate and Darolutamide in Men with Metastatic Castration-Sensitive Prostate Cancer

Registered drug

Germany

Participants:18–64 years · 65+ years
Substances:Abiraterone Acetate
Sponsor:AstraZeneca AB

Contact Research Centre

Hepatocellular carcinoma

Recruiting

Study on the Effectiveness of Durvalumab and Bevacizumab for Patients with Liver Cancer at High Risk of Recurrence After Surgery or Ablation

Registered drug

Study on the Effectiveness of Durvalumab and Bevacizumab for Patients with Liver Cancer at High Risk of Recurrence After Surgery or Ablation

Registered drug

Germany

Participants:18–64 years · 65+ years
Substances:Bevacizumab
Sponsor:AstraZeneca AB

Contact Research Centre

Hormone-refractory prostate cancer

Recruiting

Study Comparing MK-5684 with Abiraterone Acetate or Enzalutamide for Patients with Advanced Prostate Cancer After Hormonal Therapy

Registered drugNo placebo

Study Comparing MK-5684 with Abiraterone Acetate or Enzalutamide for Patients with Advanced Prostate Cancer After Hormonal Therapy

Registered drugNo placebo

Germany

Participants:18–64 years · 65+ years
Substances:Abiraterone Acetate
Sponsor:Merck Sharp & Dohme LLC

Contact Research Centre

Triple negative breast cancer+4

Recruiting

Study Comparing Sacituzumab Govitecan Alone and with Pembrolizumab for Patients with Low-Risk, Triple-Negative Early Breast Cancer

Registered drugNo placebo

Study Comparing Sacituzumab Govitecan Alone and with Pembrolizumab for Patients with Low-Risk, Triple-Negative Early Breast Cancer

Registered drugNo placebo

Germany

Participants:18–64 years · 65+ years
Substances:Pembrolizumab
Sponsor:WSG Women's Cancer Study Group GmbH

Contact Research Centre

Acute graft versus host disease

Recruiting

Study on Mesenchymal Stromal Cells (MC0518) for Treating Steroid-Resistant Acute Graft Versus Host Disease in Adults and Adolescents

Registered drugNo placebo

Study on Mesenchymal Stromal Cells (MC0518) for Treating Steroid-Resistant Acute Graft Versus Host Disease in Adults and Adolescents

Registered drugNo placebo

Germany

Participants:0–17 years · 18–64 years · 65+ years
Substances:Everolimus
Sponsor:Medac Gesellschaft fuer klinische Spezialprapaerate mbH

Contact Research Centre

Persistent corneal epithelial defect

Recruiting

Study on the Safety and Effectiveness of Lufepirsen Gel for Patients with Persistent Corneal Epithelial Defects

Investigational

Study on the Safety and Effectiveness of Lufepirsen Gel for Patients with Persistent Corneal Epithelial Defects

Investigational

Germany

Participants:18–64 years · 65+ years
Substances:Lufepirsen
Sponsor:Glaukos Corp.

Contact Research Centre

Non-Hodgkin's lymphoma

Recruiting

Study on Lymphoblastic Lymphoma Treatment in Children and Adolescents Using Dexamethasone, Prednisone, and PEG-Asparaginase

Registered drugNo placebo

Study on Lymphoblastic Lymphoma Treatment in Children and Adolescents Using Dexamethasone, Prednisone, and PEG-Asparaginase

Registered drugNo placebo

Germany

Participants:0–17 years
Substances:Cyclophosphamide
Sponsor:Universitaetsklinikum Muenster AöR

Contact Research Centre

Squamous cell carcinoma of head and neck

Recruiting

Study on the Effects of Ficlatuzumab and Cetuximab for Adults with Recurrent or Metastatic HPV-Negative Head and Neck Cancer

Registered drug

Study on the Effects of Ficlatuzumab and Cetuximab for Adults with Recurrent or Metastatic HPV-Negative Head and Neck Cancer

Registered drug

Germany

Participants:18–64 years · 65+ years
Substances:Cetuximab
Sponsor:Aveo Pharmaceuticals Inc.

Contact Research Centre

B-cell type acute leukaemia

Recruiting

Study on the Safety and Effectiveness of AZD0486 and Tocilizumab for Adolescents and Adults with Relapsed or Refractory B-Cell Acute Lymphoblastic Leukemia

Registered drugNo placebo

Study on the Safety and Effectiveness of AZD0486 and Tocilizumab for Adolescents and Adults with Relapsed or Refractory B-Cell Acute Lymphoblastic Leukemia

Registered drugNo placebo

Germany

Participants:0–17 years · 18–64 years · 65+ years
Substances:Tocilizumab
Sponsor:AstraZeneca AB

Contact Research Centre

Other cities in Germany

The busiest research cities in the country

All 516 cities in Germany

Clinical research in Freiburg Im Breisgau

What the registry says about research in the country

01 Oncology Research

Innovative trials focusing on breast cancer, non-small cell lung cancer, and colon cancer treatments. Studies evaluating new therapeutic approaches for both early-stage and advanced cancers.

Breast Cancer Therapy Optimization
Advanced Lung Cancer Treatments
Gastrointestinal Cancer Research

Emphasis on targeted therapies and combination treatments to improve patient outcomes.

02 Autoimmune Conditions

Research into treatments for psoriatic arthritis, rheumatoid arthritis, and Sjögren's disease. Studies evaluating novel biologics and targeted therapies.

Inflammatory Arthritis Management
Autoimmune Disease Therapeutics
Novel Treatment Approaches

Focus on improving disease control and quality of life for patients with chronic autoimmune conditions.

03 Rare Diseases

Clinical investigations of treatments for spinal muscular atrophy, sickle cell disease, and primary sclerosing cholangitis. Studies aimed at developing innovative therapies.

Genetic Disease Treatments
Blood Disorders
Pediatric Rare Diseases

Dedicated to finding breakthrough treatments for challenging rare conditions.

Back to Germany All countries